(Q40094506)

English

Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors

scientific article published on 13 October 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors (English)

1 reference

Europe PubMed Central

17 September 2017

Cristina Gasparetto

4

object named as

C Gasparetto

1 reference

Europe PubMed Central

17 September 2017

1

object named as

D A Rizzieri

1 reference

Europe PubMed Central

17 September 2017

8

object named as

N J Chao

1 reference

Europe PubMed Central

17 September 2017

3

object named as

G D Long

1 reference

Europe PubMed Central

17 September 2017

author name string

P Dev

2

1 reference

Europe PubMed Central

17 September 2017

K M Sullivan

5

1 reference

Europe PubMed Central

17 September 2017

Ml Horwitz

6

1 reference

Europe PubMed Central

17 September 2017

J Chute

7

1 reference

Europe PubMed Central

17 September 2017

language of work or name

0 references

publication date

13 October 2008

1 reference

Europe PubMed Central

17 September 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

17 September 2017

43

1 reference

Europe PubMed Central

17 September 2017

4

1 reference

Europe PubMed Central

17 September 2017

327-333

1 reference

Europe PubMed Central

17 September 2017

https://scigraph.springernature.com/pub.10.1038/bmt.2008.321

0 references

Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

22 September 2017

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

22 September 2017

Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

22 September 2017

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

22 September 2017

Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

22 September 2017

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

22 September 2017

Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

17 June 2018

Revised response criteria for malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635807

20 August 2018

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Donor leukocyte infusion for relapsed ANLL after allogeneic BMT and the use of interferon alpha to induce graft-versus-leukemia effect

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relapse of Philadelphia chromosome positive acute lymphoblastic leukaemia after marrow transplantation: sustained molecular remission after early and dose-escalating infusion of donor leucocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute

1 reference

https://pubmed.ncbi.nlm.nih.gov/18850014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BMT.2008.321

1 reference

Europe PubMed Central

17 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

17 September 2017

1 reference

Europe PubMed Central

17 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40094506&oldid=1885111739"